ADMA Biologics Statistics
Total Valuation
ADMA Biologics has a market cap or net worth of $2.04 billion. The enterprise value is $2.11 billion.
| Market Cap | 2.04B |
| Enterprise Value | 2.11B |
Important Dates
The next estimated earnings date is Wednesday, November 4, 2026, after market close.
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ADMA Biologics has 223.98 million shares outstanding. The number of shares has increased by 1.15% in one year.
| Current Share Class | 223.98M |
| Shares Outstanding | 223.98M |
| Shares Change (YoY) | +1.15% |
| Shares Change (QoQ) | -4.01% |
| Owned by Insiders (%) | 1.89% |
| Owned by Institutions (%) | 92.28% |
| Float | 219.66M |
Valuation Ratios
The trailing PE ratio is 13.01 and the forward PE ratio is 10.24.
| PE Ratio | 13.01 |
| Forward PE | 10.24 |
| PS Ratio | 3.98 |
| Forward PS | 3.30 |
| PB Ratio | 5.03 |
| P/TBV Ratio | 5.05 |
| P/FCF Ratio | 17.52 |
| P/OCF Ratio | 14.92 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.40, with an EV/FCF ratio of 18.10.
| EV / Earnings | 12.48 |
| EV / Sales | 4.12 |
| EV / EBITDA | 9.40 |
| EV / EBIT | 9.74 |
| EV / FCF | 18.10 |
Financial Position
The company has a current ratio of 6.97, with a Debt / Equity ratio of 0.50.
| Current Ratio | 6.97 |
| Quick Ratio | 3.62 |
| Debt / Equity | 0.50 |
| Debt / EBITDA | 0.90 |
| Debt / FCF | 1.75 |
| Interest Coverage | 24.53 |
Financial Efficiency
Return on equity (ROE) is 41.90% and return on invested capital (ROIC) is 36.24%.
| Return on Equity (ROE) | 41.90% |
| Return on Assets (ROA) | 21.78% |
| Return on Invested Capital (ROIC) | 36.24% |
| Return on Capital Employed (ROCE) | 35.58% |
| Weighted Average Cost of Capital (WACC) | 8.05% |
| Revenue Per Employee | $791,770 |
| Profits Per Employee | $261,141 |
| Employee Count | 647 |
| Asset Turnover | 0.82 |
| Inventory Turnover | 0.84 |
Taxes
In the past 12 months, ADMA Biologics has paid $47.52 million in taxes.
| Income Tax | 47.52M |
| Effective Tax Rate | 21.95% |
Stock Price Statistics
The stock price has decreased by -41.45% in the last 52 weeks. The beta is 0.77, so ADMA Biologics's price volatility has been lower than the market average.
| Beta (5Y) | 0.77 |
| 52-Week Price Change | -41.45% |
| 50-Day Moving Average | 9.20 |
| 200-Day Moving Average | 12.25 |
| Relative Strength Index (RSI) | 46.40 |
| Average Volume (20 Days) | 2,513,512 |
Short Selling Information
The latest short interest is 23.87 million, so 10.66% of the outstanding shares have been sold short.
| Short Interest | 23.87M |
| Short Previous Month | 22.68M |
| Short % of Shares Out | 10.66% |
| Short % of Float | 10.87% |
| Short Ratio (days to cover) | 10.58 |
Income Statement
In the last 12 months, ADMA Biologics had revenue of $512.28 million and earned $168.96 million in profits. Earnings per share was $0.70.
| Revenue | 512.28M |
| Gross Profit | 331.47M |
| Operating Income | 216.50M |
| Pretax Income | 216.48M |
| Net Income | 168.96M |
| EBITDA | 224.19M |
| EBIT | 216.50M |
| Earnings Per Share (EPS) | $0.70 |
Balance Sheet
The company has $136.02 million in cash and $203.84 million in debt, with a net cash position of -$67.82 million or -$0.30 per share.
| Cash & Cash Equivalents | 136.02M |
| Total Debt | 203.84M |
| Net Cash | -67.82M |
| Net Cash Per Share | -$0.30 |
| Equity (Book Value) | 408.21M |
| Book Value Per Share | 1.81 |
| Working Capital | 452.45M |
Cash Flow
In the last 12 months, operating cash flow was $136.72 million and capital expenditures -$20.25 million, giving a free cash flow of $116.47 million.
| Operating Cash Flow | 136.72M |
| Capital Expenditures | -20.25M |
| Depreciation & Amortization | 7.69M |
| Net Borrowing | 123.12M |
| Free Cash Flow | 116.47M |
| FCF Per Share | $0.52 |
Margins
Gross margin is 64.71%, with operating and profit margins of 42.26% and 32.98%.
| Gross Margin | 64.71% |
| Operating Margin | 42.26% |
| Pretax Margin | 42.26% |
| Profit Margin | 32.98% |
| EBITDA Margin | 43.76% |
| EBIT Margin | 42.26% |
| FCF Margin | 22.74% |
Dividends & Yields
ADMA Biologics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.15% |
| Shareholder Yield | -1.15% |
| Earnings Yield | 8.28% |
| FCF Yield | 5.71% |
Analyst Forecast
The average price target for ADMA Biologics is $17.00, which is 86.61% higher than the current price. The consensus rating is "Buy".
| Price Target | $17.00 |
| Price Target Difference | 86.61% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 12.65% |
| EPS Growth Forecast (3Y) | 22.26% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ADMA Biologics has an Altman Z-Score of 10.04 and a Piotroski F-Score of 5.
| Altman Z-Score | 10.04 |
| Piotroski F-Score | 5 |